Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 0.81 |
| ▸ | DRD4 | P21917 | 10/20 | 0.77 |
| ▸ | DRD3 | P35462 | 10/20 | 0.77 |
| ▸ | DRD1 | P21728 | 3/20 | 0.74 |
| ▸ | DRD5 | P21918 | 3/20 | 0.74 |
| ▸ | HTR2A | P28223 | 3/20 | 0.74 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | MLNR | O43193 | 1/20 | 0.74 |
| ▸ | HTR3B | O95264 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | ESR1 | P03372 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.74 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532795 | 0.89 | DRD2 (1.00) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL252295 | 0.87 | DRD2 (1.00) | DRD2DRD4DRD3 | |
| SCHEMBL10571409 | 0.86 | DRD2 (0.94) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL10665990 | 0.86 | DRD2 (1.00) | DRD2DRD4DRD3MAOA | |
| SCHEMBL5609347 | 0.86 | DRD2 (0.76) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL30751117 | 0.86 | DRD2 (0.76) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL14974690 | 0.86 | DRD2 (1.00) | DRD2DRD4DRD3 | |
| SCHEMBL8078 | 0.86 | DRD2 (1.00) | DRD2DRD4DRD3 | |
| SCHEMBL10572858 | 0.85 | DRD2 (0.94) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL10576593 | 0.85 | DRD2 (0.98) | DRD2DRD4DRD3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247420-B2 | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247420-B2 | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247420-B2 | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-2162135-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | Reviva Pharmaceuticals, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008144764-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144764-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | GRIN2D, GRIN2C, AP3D1 | DRD2 26/4885DRD4 38/4885DRD3 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.